

Article

Bifidobacterium animalis subsp. *animalis* GY007 Mitigates High Fluoride Exposure-Induced Ileal Injury and Restores the Ileal Microbiota–Metabolome Imbalances

Yu Chen, Yan Zeng, Bo Jing, Dong Zeng and Xueqin Ni *

Animal Microecology Institute, College of Veterinary Medicine, Sichuan Agricultural University, No. 211 Huimin Road, Wenjiang District, Chengdu 611130, China

* Correspondence: xueqinni@foxmail.com

Simple Summary

This study investigated the protective effects of *Bifidobacterium animalis* subsp. *animalis* GY007 against ileal injury resulting from fluoride exposure. Three cohorts of experimental mice were examined: a healthy control group (Ctrl), a fluoride exposed group (F), and a group co-treated with both fluoride and the probiotic GY007 (F+Bi). The findings demonstrated that GY007 administration significantly mitigated fluoride-induced ileal injury in mice. This protective effect was evidenced by reduced intestinal permeability, increased expression of tight junction proteins, restoration of ileal mucosal architecture, and decreased oxidative stress levels. In parallel, inflammatory cytokines and markers associated with the TLR9/NF- κ B/IRF7 pathway were reduced (TLR9, Myd88, IRAK4, NF- κ B, IRF7, TNF- α , IL-6, and IFN- α). Analysis of the microbiome and metabolome demonstrated that GY007 influenced the structure of the ileal microbial community and its associated metabolite profile. Our results suggest that GY007 may play a beneficial role in mitigating fluoride-induced ileal injury and shed light on the alterations in the gut microbial community and metabolome. This study provides new insights into how probiotic repairs the damaged ileum caused by endogenous fluoride exposure through interactions with the host organism.

Abstract

Exposure to fluoride is strongly associated with impaired intestinal function. Probiotics are widely regarded as an effective strategy to maintain microbial homeostasis and to mitigate the progression of fluoride-induced intestinal injury. This study aimed to evaluate the measurable protective effects of the probiotic strain *Bifidobacterium animalis* subsp. *animalis* (*B. animalis* subsp. *animalis*) GY007 in reversing high fluoride-induced ileal injury. The results showed that GY007 (1×10^9 CFU/mL, once/daily) attenuated intestinal barrier disruption and alleviated ileal mucosal abnormalities in mice receiving fluoride (24 mg/kg) by gavage for eight consecutive weeks. GY007 attenuated elevated oxidative stress and modulated the inflammatory response associated with the TLR9/NF- κ B/IRF7 signaling pathway. Microbiome and metabolomic analyses showed that GY007 reversed the dysregulation of the ileal microbial community structure and metabolite profiles. Spearman's rank correlation analysis further supported a regulatory role for *Bifidobacterium* in this protective process and identified three key functional metabolites meriting further investigation: isocytosine (ISO), 7 α ,24S-dihydroxy-3-oxocholest-4-en-26-oic acid (OIC-7 α), and sinapinic acid (SIA). Our findings demonstrate that GY007 protects against fluoride-induced ileal injury and elucidate the associated changes in the intestinal microbial community and metabolite profiles. This study provides new evidence clarifying the restorative effect



Academic Editor: Hao Zhong

Received: 26 December 2025

Revised: 3 February 2026

Accepted: 4 February 2026

Published: 28 February 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and

conditions of the [Creative Commons](https://creativecommons.org/licenses/by/4.0/)

Attribution (CC BY) license.

of the probiotic GY007 on the ileum under environmental fluoride exposure, offering an integrative perspective on the interaction between microorganisms and their host.

Keywords: high fluoride exposure; probiotics; ileal injury; metabolomics; 16S rRNA high throughput sequencing

1. Introduction

As the thirteenth most prevalent element in the Earth's crust, fluorine is broadly distributed across natural and artificial environments [1]. Human exposure to fluorides occurs through several routes: 60% via water, 35% via food, and 5% via air [2]. Long-term excessive intake of fluoride has exposed more than 200 million people in more than 50 countries to high levels of fluoride, making it a global public health problem [3,4]. Fluoride pollution predominantly impacts populations in Africa (37–46% of the total population) and Asia (51–59% of the total population) [5]. Fluoride pollution is a widespread issue across 31 provincial-level regions in China, both north and south, impacting nearly 60 million individuals living in 80,011 villages [6]. It is estimated that in India, the onset of disease in approximately 62 million people is closely associated with exposure to fluoride-contaminated groundwater, of which about 6 million are children [7]. High fluoride intake is associated with dental and skeletal fluorosis and extra-skeletal toxicity (e.g., brain, kidney, and gastrointestinal tract), potentially leading to chronic pain, functional limitations, and reduced quality of life [8–10]. These health effects also impose economic burdens through increased healthcare costs, productivity losses, and long-term care needs; in a field survey from fluorosis-endemic regions in India, per capita expenditures attributable to fluorosis were INR 5454–14,815 [10,11]. Anthropogenic activities, including the production of fertilizers, operation of brick kilns, manufacture of glass, and smelting of aluminum, contribute to the accumulation and pollution of fluorides [12]. The fertilizer industry alone generates approximately 5.4 to 11.8 million tons of fluoride waste each year [12]. An analysis of 25 soil samples from the area surrounding an aluminum smelter in south-western China revealed fluorine concentrations of up to 4000 mg/kg, compared to a global average of 400 mg/kg in soil [13]. Fluorine is absorbed by plants from polluted soils and aquatic environments, subsequently entering the human food chain [5].

The digestive system is the primary route for the absorption of fluoride. The gut is generally one of the first areas to be impacted by its effects [14]. Based on previous reports, the exposure to fluoride was associated with structural changes in the intestinal tissue, notably the thinning of the muscularis layer and sparse microvilli [15–17]. Marked edema, villus shortening, and villus coalescence were observed in the small intestine, accompanied by increased circulating concentrations of d-lactic acid and diamine oxidase [18]. Significant factors that disrupt the intestinal homeostasis can stimulate the secretion of inflammatory cytokines, thereby leading to chronic inflammation [19]. Our prior research has demonstrated that fluoride exposure in drinking water for 70 days was associated with the dysbiosis of the murine ileal microbiome, heightened intestinal permeability, and aberrant inflammatory responses [20,21]. More recently, our team found that sodium fluoride (NaF) given by gavage with 24 mg/kg body weight (bw) for 8 consecutive weeks induced villus damage and shortening in the murine small intestine, accompanied by an evident decrease in the proportional relationship between villus height and crypt depth [22]. Further research revealed that the potential mechanism underlying ileal injury in mice exposed to 50 ppm NaF in drinking water for 56 consecutive weeks may be associated with the mucus barrier and immune response through single-cell sequencing analysis [14].

Moreover, antibiotic-induced disruption of the ileal microbiota was shown to attenuate ileal injury induced by oral gavage administration of NaF at 24 mg/kg bw for 8 weeks [14]. These findings suggest that the ileum warrants significant attention in both intestinal and systemic diseases induced by fluoride exposure, and that microbial community intervention may present a novel therapeutic approach for fluoride-related pathologies.

Current strategies to mitigate excessive fluoride exposure focus primarily on reducing intake at the source, notably by providing low-fluoride water and implementing defluoridation technologies (e.g., adsorption using activated alumina/bone char, precipitation-based approaches, ion exchange, and membrane/separation techniques) [23–25]. Furthermore, previous studies have reported that vitamin C and vitamin E can attenuate fluoride-induced damage in experimental animals [26,27]. Miao et al. found that selenium supplementation was associated with increased superoxide dismutase (SOD) activity, reduced fluoride-related toxicity, and improved indicators of liver function [28]. In humans, dietary calcium may help reduce fluoride absorption and mitigate fluoride toxicity [29–31]. However, studies investigating probiotics in fluoride-induced ileal injury remain limited.

Probiotics are colonies of live microorganisms that offer quantifiable health benefits. By regulating the gut microbiota, they could maintain intestinal barrier function, regulate immune function, and stimulate the generation of circulating metabolites that exert systemic effects [32]. *Bifidobacterium* constitutes one of the most significant bacterial taxa in the human intestine, with its characteristics and mechanisms of action having been extensively documented since 1950 [33–35]. Over the past two decades, multiple probiotic candidates from the *Bifidobacterium* and *Lactobacillus* genera have been shown in experimental and clinical studies to reduce manifestations associated with intestinal injury [36–39]. A recent study found that male mice with *Bifidobacterium* supplementation showed a reduction in the damage to the high-fat diet-driven impairment of the gut barrier [40]. A random trial involving 100 students with diarrhea showed that taking *Bifidobacterium* could effectively alleviate diarrhea symptoms and restore the disrupted intestinal flora caused by diarrhea [41]. Furthermore, our group's previous research demonstrated that *Lactobacillus johnsonii* BS15 could restore ileal microbial dysbiosis, heightened intestinal permeability, and aberrant inflammatory responses resulting from fluoride exposure in drinking water, concurrently ameliorating hippocampal injury in mice [20,21]. This suggests that probiotic intervention in the ileum could offer a means of preventing and treating intestinal and extraintestinal diseases induced by fluoride. However, even when classified within a single species, distinct probiotic strains could display markedly divergent characteristics and may yield substantially different clinical outcomes. Consequently, further investigation is required to establish the effectiveness of a beneficial probiotic strain [42]. Discovering and studying the probiotic properties of more bacterial strains in specific application scenarios not only provides more bacterial strain resources, but also offers more possibilities for future disease prevention and treatment.

The potential beneficial impacts of *B. animalis* subsp. *animalis* GY007 on ileal dysfunction and ecological imbalance caused by fluoride were assessed in this study. Our research may offer a conceptual framework to support the use of probiotic interventions for managing the intestinal injury associated with excessive fluoride exposure.

2. Materials and Methods

2.1. Bacterial Strain and Culture

The strain GY007 was stored in the China center for type culture collection with preservation number CCTCC AB 2025172. GY007 was purified and inoculated into the prepared culture medium broth at 37 °C for 24 h and subcultured for three generations, to ensure activity. The third-generation bacterial suspension was centrifuged at 4000 g for

15 min and resuspended in normal saline, which was repeated three times for washing. The concentration of GY007 was adjusted to 1×10^9 CFU mL⁻¹ using the colony counting method for in vivo experiments.

2.2. Animal and Experiment Design

As shown in Figure 1A, the C57BL/6J mice (male, 3 weeks old) were procured from Si Pei Fu and maintained under standard caging conditions. Throughout the experiment, animals were housed under standardized housing parameters (20–22 °C) with a 12:12 h light–dark cycle, and six mice were accommodated in each cage. Mice were maintained with free access to standard chow and water (i.e., food and water were continuously available and not restricted) and monitored daily for health. Following a 7-day acclimation period, the animals were randomly allocated to three groups ($n = 12$ per group): a control group (Ctrl), a fluoride-exposed group (F), and a fluoride-exposed group supplemented with GY007 (F+Bi). All treatments were administered once daily via oral gavage, with the following treatment. The F+Bi group received sequential gavage of two 0.2 mL preparations: a fluoride solution (24 mg/kg, dissolved in normal saline) and a GY007 bacterial suspension (1×10^9 CFU/mL, prepared in normal saline). The F group was gavaged with an identical volume of the fluoride solution (0.2 mL), followed by 0.2 mL of normal saline. The Ctrl group was administered an equivalent total volume of normal saline alone. All the experimental procedures lasted for eight weeks. The doses of fluoride solution and duration of the experiment were as given in previous studies [14,22].




Figure 1. Trial protocol and index testing of blood. (A) Overview of the experimental design for GY007 intervention under fluoride exposure. (B,C) DAO and D-lactate content ($n = 8$). Data are presented as mean $\pm$ standard deviation. D-Lactate: Wilcoxon rank-sum test. DAO: One-way ANOVA. * $p < 0.05$, *** $p < 0.001$ were considered significant, and NS means no significant difference.

On the final day of the 8-week experimental period, blood was collected by retro-orbital sampling from mice. The blood samples were centrifuged to isolate the serum, which was then stored at -80 °C for testing. All mice were culled by cervical dislocation and sampling was conducted immediately. The ileum was excised and opened; luminal contents

were gently scraped into sterile tubes. Ileal contents were promptly frozen at -80°C for subsequent 16S rRNA high-throughput sequencing and non-targeted metabolomics. The collected ileal tissue was flushed with ice-cold saline, cut into small pieces and immediately stored at -80°C for testing. All procedures were performed on ice. The partial ileal tissue without intraluminal material was in 4% paraformaldehyde solution and partial ileal tissues containing luminal content were in methanol-carnoy for at least 24 h for fixation.

2.3. Metabolite Detection and Bioinformatics Analysis

A total of 24 ileal contents samples were performed to untargeted metabolite profiling, with 8 samples per group. Metabolite profiling and the associated bioinformatics workflows were carried out in accordance with procedures reported previously [43].

2.4. 16S rRNA Sequencing and Analysis

A total of 24 ileal contents samples were performed to 16S rRNA sequencing, with 8 samples per group, corresponding to the metabolite detection samples. Briefly, ileal content DNA was extracted using the E.Z.N.A. Stool DNA Kit. The V3–V4 region of the 16S rRNA gene was amplified with barcoded primers 338F/806R, and amplicons were purified, quantified, pooled in equimolar amounts, and sequenced on an Illumina MiSeq platform (2×250 bp, paired-end). Reads were processed in QIIME2 2024.5 [44] for demultiplexing, primer trimming, quality control, and denoising/merging/chimera removal with DADA2 [45]; ASVs were aligned with MAFFT [46] and a phylogeny was built with FastTree2 [47]. Taxonomy was assigned using a Naive Bayes classifier against Greengenes2 2022.10 [48,49]. Alpha diversity (Shannon, Simpson), beta diversity (Bray–Curtis; PCoA), and PERMANOVA were performed in QIIME2 and R V4.3.3 [50,51]. Random forest was used to discriminate groups, and Mantel and Spearman correlation analyses were applied to assess microbiota–metabolome and phenotype associations [52,53]. Detailed information is provided in the Supplementary File S1.

2.5. Real-Time Quantitative PCR (RT-qPCR) of mRNA Expression Levels

Five specimens from each experimental group were randomly chosen (15 in total) for RNA isolation in this part. Total RNA from ileal tissue was extracted using procedures that have been reported previously [22]. Primer information is provided in Supplementary Table S1.

2.6. Histology

The subsequent steps were the same as described in the previous research [43]. The anti-MUC2 (1:500), anti-4-HNE (1:100), anti-ZO-1 (1:100), anti-Claudin-1 (1:50), anti-Occludin (1:500), anti-IRF7 (1:1000), anti-TLR9 (1:100), anti-NF- κ B (1:1000), anti-IRAK4 (1:1000), and anti-Myd88 (1:200) were used to assess the condition of the ileal tissue.

2.7. Biochemical Analysis

The serum samples and the ileal tissue were estimated. The blood samples were centrifuged at $3000 \times g$ for 15 min at 4°C . Subsequently, serum diamine oxidase (DAO) and D-lactate were measured using mouse-specific ELISA kits (Jiangsu Enzyme Technology, Yancheng, Jiangsu, China). Antioxidant indices in the ileal tissue were measured using commercial kits (Jiancheng Bioengineering Institute, Nanjing, Jiangsu, China), including total antioxidant capacity (T-AOC; A015-3-1), catalase (CAT; A007-1-1), reduced glutathione (GSH; A006-2-1), malondialdehyde (MDA; A003-1-2), hydrogen peroxide (H_2O_2 ; A064-1-1), and superoxide dismutase (SOD; A001-3-2).

2.8. Statistical Analysis

Normal distributions were assessed using the Shapiro–Wilk normality test. If the data were not normally distributed, normality tests were repeated after log-transformation. Normally distributed data with homogeneity of variance were analyzed using *t*-tests (two independent samples) or one-way ANOVA with LSD post hoc multiple analysis (comparisons among multiple groups). Normally distributed data with heterogeneity of variance among multiple groups were analyzed using one-way ANOVA with Dunnett's T3 post hoc analysis. Data that did not reach a normal distribution were tested using the Kruskal–Wallis test at $p < 0.05$, followed by the Wilcoxon rank-sum test. Data are presented as the mean $\pm$ standard deviation and were analyzed using IBM SPSS Statistics 27. * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ were considered significant. The mapping software used was GraphPad Software 8.0.

3. Results

3.1. GY007 Could Alleviate Intestinal Barrier Damage Induced by Fluoride

Consistent with the animal handling protocol outlined above, serum samples were obtained from the mice (Figure 1A). As illustrated in Figure 1B,C, the F group exhibited markedly ($p < 0.001$) higher levels of D-lactate and DAO than control mice. Mice receiving GY007 (F+Bi) displayed reduced circulating D-lactate and DAO concentrations, relative to the F group ($p < 0.05$). For both parameters, the Ctrl and F+Bi groups did not differ significantly ($p > 0.05$). Tight junction proteins were assessed in the ileal tissue of the mice. In the F group, both mRNA expression and protein levels of Claudin-1 (Figure 2A,B), Occludin (Figure 2D,E) and ZO-1 (Figure 2G,H) were markedly decreased in comparison to the remaining groups ($p < 0.05$). Treatment of GY007 significantly restored these markers ($p < 0.05$), with no significant difference observed between the Ctrl and F+Bi ($p > 0.05$). To evaluate the in situ expression patterns of these proteins, immunofluorescence staining was carried out thereafter. As depicted in Figure 2C,F,I, a significant decrease in these proteins was detected in the F group versus Ctrl, while GY007 administration restored their expression to levels comparable with those observed in controls. Overall, the results indicated that fluoride would cause enhanced intestinal permeability of the ileum and decreased expression of tight junction proteins, while GY007 could inhibit this negative impact.

3.2. GY007 Could Repair the Ileal Oxidative Damage Induced by Fluoride

Analyses were conducted to further evaluate the oxidative stress profile in the mouse ileum. Significant variations ($p < 0.05$) of SOD (Figure 3B) and CAT (Figure 3D) activities together with MDA (Figure 3A), T-AOC (Figure 3C), and H_2O_2 (Figure 3E) contents were observed in the F group. Administration of GY007 significantly modulated MDA, SOD, T-AOC, and CAT measurements ($p < 0.01$), restoring these indices to values that were not statistically different from those in the Ctrl group with no significant difference observed between the Ctrl and F+Bi ($p > 0.05$). Although GY007 treatment was able to significantly reverse ($p < 0.05$) the trend of fluoride-induced accumulation of H_2O_2 in the ileum, H_2O_2 levels remained substantially higher than the Ctrl group ($p < 0.05$). Meanwhile, across the groups, no statistically meaningful differences were observed, regardless of whether fluoride exposure or GY007 dosing was applied ($p > 0.05$, Figure 3F). Then, the mRNA expressions of *Duox2* and *Duoxa2* were detected. As presented in Figure 3G,H, fluoride exposure led to significantly upregulated ($p < 0.05$) ileal *Duox2* and *Duoxa2* mRNA levels relative to the Ctrl group, while GY007 could significantly reverse ($p < 0.01$) this trend. Further immunofluorescence results confirmed that the lipid peroxidation reaction in the F group was enhanced. The use of GY007 could reduce the lipid peroxidation reaction in the

ileum of mice (Figure 3I). In aggregate, these data implied that fluoride causes oxidative stress damage to the ileum of mice, while the use of GY007 could partially alleviate these adverse effects.




Figure 2. Change in ileal tight junction protein expression. (A,D,G) Relative mRNA expression of *Claudin1*, *Occludin* and *ZO-1* in the ileum ($n = 5$). (B,E,H) The protein levels of *Claudin1*, *Occludin* and *ZO-1* in the ileum ($n = 8$). (C,F,I) Representative immunofluorescence image of *Claudin1*, *Occludin* and *ZO-1*. *Claudin-1*, *Occludin*, and *ZO-1* signals are shown in red. Data are presented as mean $\pm$ standard deviation. The mRNA expression levels of *Claudin1* and *Occludin*; the protein levels of *Occludin* were analyzed using the Wilcoxon rank-sum test. The remaining: One-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and NS means no significant difference.

3.3. The Influences of Fluoride Exposure and Probiotic GY007 on Function and Mucus Layer of the Ileum

Reg3a, *b*, *g*, *MUC2* and *Ramp1* are important indicators for characterizing intestinal homeostasis and function [54]. Therefore, the mRNA expression levels of them were further examined. After fluoride treatment, ileal mRNA levels of *Reg3a*, *b*, *g* and *MUC2* were reduced, consistent with a loss of intestinal homeostasis ($p < 0.01$, Figure 4A–D). The application of GY007 could significantly reverse the transcriptional levels of them ($p < 0.05$) to values comparable with the Ctrl group (except for *Reg3a*). Immunofluorescence analyses suggested that the staining intensity of *MUC2* and *Ramp1* were diminished in the ileum of mice exposed to fluoride, while the use of GY007 could enhance the expression (Figure 4E,F). *MUC2* serves as a key scaffolding element within the external mucous barrier layer [55]. More detailed examination of the defining features of mucus in the ileum was observed. Evaluating intestinal mucus characteristics in fixed tissue slices remains difficult, largely because mucus preservation in fixed specimens is inconsistent [56]. Fixed sections from the Ctrl, F, and F+Bi groups were subjected to Alcian blue–periodic acid–Schiff (AB/PAS)

staining and inspected to assess whether fluoride treatment and GY007 administration produced changes in the intestinal mucus (Figure 4G). In comparison with the Ctrl, the surface of the ileal villi and the mucus in the inter-villus spaces in the F group decreased, while the F+Bi group showed a trend toward restoration. Glycogen, neutral mucoprotein, and various glycoproteins appear purple-red, while acidic mucoprotein, proteoglycan and hyaluronic acid appear blue in the AB/PAS staining. The mucin components in the F group were particularly different, more resembling acidic mucopolysaccharides, while the F+Bi group and the Ctrl group were more similar to neutral mucopolysaccharides. These results suggest that fluoride exposure compromises the intestinal homeostasis, function and mucus properties of the ileum, while GY007 could produce a positive effect.




Figure 3. The influence of high fluoride exposure and GY007 on antioxidant capacity in the ileum. (A–F) Activities or contents ($n = 8$) of MDA, SOD, T-AOC, CAT, H₂O₂, and GSH. (G,H) The mRNA expression levels ($n = 5$) of *Duox2* and *Duoxa2*. (I) Representative immunofluorescence image of 4-HNE. The protein expressions of 4-HNE are stained red. Data are presented as mean $\pm$ standard deviation. SOD and GSH: Wilcoxon rank-sum test. The remaining: One-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and NS means no significant difference.




Figure 4. Assessment of ileal function and mucus layer. (A–D) The mRNA expression levels ($n = 5$) of *Reg3a*, *Reg3b*, *Reg3g*, and *MUC2*. (E,F) Representative immunofluorescence image of MUC2 and Ramp1. The protein expressions of MUC2 and Ramp1 are stained red. (G) AB/PAS-stained fixed tissue sections. The red arrow represents the ileal mucus. Data are presented as mean $\pm$ standard deviation. One-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and NS means no significant difference.

3.4. Impacts of Fluoride Exposure and GY007 on Toll-like Receptor (TLR) Signaling Pathway and Downstream Inflammatory-Related Factors

TLR-mediated signaling has been widely investigated as a key mechanism through which probiotics influence host regulatory processes. The interaction between them could trigger local immune responses in the intestine, which may affect the homeostasis and communication within the body [57]. This part focused on the levels of key components within the TLR signaling pathway of the ileum in mice (Figure S1). As shown in Figure 5A–F, GY007 significantly decreased the mRNA expression and protein content of $\text{TNF-}\alpha$, IL-6 , and $\text{IFN-}\alpha$ within the murine ileum ($p < 0.01$), restoring them to levels not significantly different from those of the control mice. We detected *IL17*, *IL-10*, and

IFN- γ , additionally (Figure 5G–I). Fluoride administration markedly elevated ($p < 0.01$) the level of mRNA expression of *IL-17* in the ileum. GY007 had a reversing trend but no statistical significance ($p = 0.062$). Across the three groups, *IL-10* and *IFN- γ* levels did not differ significantly ($p > 0.05$). As shown in Figure 6, GY007 significantly attenuated the fluoride-induced upregulation of ileal *IRAK4*, *IRF7*, *Myd88*, *NF- κ b*, and *TLR9* mRNA levels ($p < 0.05$). Immunofluorescence assay showed a trend consistent with the mRNA expression levels. Notably, the mRNA levels of *TLR2*, *TLR3*, *TLR5*, *TLR7*, and *TLR8* did not differ significantly across the experimental groups ($p > 0.05$, Figure S2A–E). In the F group, *TLR4* mRNA expression was markedly elevated ($p < 0.05$), while GY007 showed a tendency towards a decrease that did not achieve statistical significance (Figure 2F). These results suggest that GY007 may modulate the changes in *TNF- α* , *IL-6*, and *IFN- α* levels caused by fluoride exposure through *TLR9*, although a direct causal relationship has not been functionally validated.




Figure 5. Assessment of ileal inflammatory mediator levels. (A–C) The mRNA expression levels ($n = 5$) of *TNF- α* , *IL-6*, and *IFN- α* . (D–F) The protein levels ($n = 8$) of *TNF- α* , *IL-6* and *IFN- α* in the ileum. (G–I) The mRNA expression levels ($n = 5$) of *IL-17*, *IL-10*, and *IFN- γ* . Data are presented as mean $\pm$ standard deviation. The protein levels of *TNF- α* were analyzed using the Wilcoxon rank-sum test. The remaining: One-way ANOVA. ** $p < 0.01$, *** $p < 0.001$, and NS means no significant difference.




Figure 6. Assessment of key molecules associated with the ileal Toll-like receptor pathway. The mRNA expression levels ($n = 5$) of (A) *IRAK4*, (C) *IRF7*, (E) *NF-κB*, (G) *Myd88*, and (I) *TLR9*. Representative immunofluorescence image of (B) *IRAK4*, (D) *IRF7*, (F) *NF-κB*, (H) *Myd88*, and (J) *TLR9*. The protein expressions of *IRAK4*, *IRF7*, *NF-κB*, *Myd88*, and *TLR9* are stained red. Data are presented as mean $\pm$ standard deviation. *NF-κB* and *IRAK4*: Wilcoxon rank-sum test. The remaining: One-way ANOVA. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and NS means no significant difference.

3.5. GY007 Could Restore Microbial Structure in High Fluoride Exposure-Induced Ileal Injury

To explore the function of probiotics from a microbiological perspective, the 16S rRNA high-throughput sequencing of the ileal content was conducted. Rarefaction analysis assessed the observed species across the collected samples. The findings indicated that, in each of the three cohorts, the accumulation of detected genes approached a plateau, suggesting that sequencing depth was sufficient to capture most of the measurable diversity (Figure S3A). As illustrated in Figure 7A, alpha diversity analysis showed that the F group had a significantly lower Simpson index than the Ctrl group ($p < 0.05$). In contrast, the Shannon diversity index exhibited a decreasing trend in the F group, although this change did not reach statistical significance ($p > 0.05$). GY007 could significantly reverse the reduction in diversity caused by fluoride ($p < 0.05$). As shown in Figure 7B, the microbial communities among the three groups each exhibited unique patterns ($p < 0.001$, $R^2 = 0.46$). The intestinal microbial distribution structure of F+Bi was more similar to that of the control. Analysis at the phylum-level profiling indicated that the ileal microbiome mainly comprised Firmicutes_D, Actinobacteriota, Bacteroidota, Desulfobacterota_I, and Firmicutes_A (Figure 7C). It is worth noting that the abundances of Firmicutes_A and Actinobacteriota within the mouse ileum was significantly changed after fluoride exposure

($p < 0.001$), while GY007 could significantly reverse this trend ($p < 0.05$, Figure S3B). Genus-level composition in the top five genera predominantly comprised *Lactobacillus*, *Limosilactobacillus*, *Dubosiella*, *Bifidobacterium*, and *Ligilactobacillus* (Figure 7D). Both the LEfSe procedure and a random forest model from machine learning workflows provided additional evidence of pronounced differences in gut microbial composition across the three groups. Also, seven biomarkers were simultaneously identified by both methods (Figures 7E,F and S3C). Within the set of marker genera identified, in comparison with the control mice, fluoride exposure significantly altered the abundance of the majority of these taxa ($p < 0.01$, Figure 7G). Although there was no statistical significance, the presence of GY007 tended to make the abundances of these markers closer to those of the Ctrl group, even in *Dubosiella* (Figure 7G). These observations indicated that fluoride exposure may disrupt the diversity and structure of the ileum microbiota, whereas GY007 could relieve this condition.




Figure 7. The effects of fluoride exposure and GY007 intervention on the characteristics of the ileum microbial community. (A) The assessment of alpha diversity based on Shannon and Simpson indices. (B) Unconstrained PCoA ordinations by Bray–Curtis dissimilarity in ileum. (C,D) Species composition at the phylum level and the genus level. (E) LDA effect size (LEfSe) analysis based on LDA > 2. (F) Random forest based on machine learning. (G) The abundance changes in key bacterial genera among the three groups. $n = 8$. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

3.6. Effects of GY007 on Ileal Metabolic Profiles in Mice Subjected to Fluoride Exposure

To assess ileal metabolic alterations in fluoride-exposed mice following administration of GY007, the metabolomics analysis was conducted. In total, 2479 metabolites were detected, comprising 1224 acquired in positive ion (POS) and 1255 acquired in negative ion (NEG). Based on LC–MS-derived ileal profiles, the PCA score plots demonstrated distinct clustering of the Ctrl and F groups in both of the ion acquisition modes (Figure 8A,B). Following GY007 administration, samples from the F+Bi group generally shifted away

from the F group in the multivariate space, although partial overlap persisted (Figure 8C,D). These findings suggested that GY007 administration partially mitigates fluoride-induced metabolic dysfunction and may confer a protective effect on the ileum. To identify metabolites exhibiting statistically significant differences across the three groups, variables meeting the thresholds of a VIP > 1 and a $p < 0.05$ were selected as differentially expressed metabolites (DEMs). A total of 295 DEMs were detected in the F versus F+Bi contrast; 346 DEMs were found when comparing Ctrl with F (Figure 8E, Tables S2 and S3). When evaluating the differences between the Ctrl and F groups, 169 were upregulated and 177 were downregulated in the F group (Figure 8E, Table S2). When evaluating differences between the F and F+Bi group, 175 were downregulated and 120 were upregulated in the F+Bi group (Figure 8F, Table S3). The Venn diagram in Figure 8G shows that the 111 common DEMs were detected in both comparisons (Figure 8E). The expression profiles of 27 upregulated and 21 downregulated metabolites in F were significantly restored in the F+Bi. We focused on the changes of nine specific DEMs. The accumulation of hippuric acid could lead to the excessive production of the total in vivo level of reactive oxygen species [58]. Isocytosine is the positional isomer of cytosine and is involved in the metabolism of bacteria [59]. MN6249 (hippuric acid, HIA) and MP3188 (isocytosine, ISO) were observed to increase in F and decrease in F+Bi ($p < 0.01$, Figure 8F,G). The concentration of bile acids in the mice exposed to the fluoride environment is worthy of attention [60]. As shown in Figure 8H–K, four bile acids, alcohols and their derivatives, including MN18188 (TRI), MN18722 (OIC-7 α), MP21633 (OIC-3), and MP22898 (OIC-3 α), showed a significant reduction in the F group ($p < 0.05$). GY007 could reverse this trend ($p < 0.05$). 18-Glycyrrhetic acid [61], Saikosaponin B2 [62] and Sinapinic acid [63] could have anti-inflammatory and antioxidant stress effects. GY007 could markedly reverse ($p < 0.05$) the decrease in the abundance of MN19753 (18-Glycyrrhetic acid, GLA), MP26064 (Saikosaponin B2, SAB), and MP9998 (sinapinic acid, SIA) caused by fluoride (Figure 8L–N). Based on the 13 markers for inflammatory bowel disease identified by the cohorts [64], seven of them were annotated and evaluated in this study. Except for MN6908 (L-Carnitine) and MN7724 (L-Tryptophan), the remaining metabolites showed no significant differences among the three groups (Figure S4). Bubble plots were employed to depict the key metabolic pathways most strongly enriched by the identified biomarkers in the two comparisons (Figure 8O,P). The metabolites of Ctrl vs. F were mainly involved in bile secretion, ABC transporters, and histidine metabolism (Figure 8O). There were four pathways enriched in F vs. F+Bi, namely purine metabolism, histidine metabolism, longevity regulating pathway, and arachidonic acid metabolism (Figure 8P).

3.7. Relevance Analysis of the Microbiota and Metabolism with Ileal Function Variables

To clarify how ileal molecules may mediate the probiotic-driven restoration of fluoride-induced intestinal injury, we integrated the datasets generated above—namely, key genera identified by 16S rRNA sequencing and representative DEMs from the metabolomics screen—and subsequently performed Pearson correlation and Mantel test analyses. As shown in Figure 9A, the obtained results confirmed that there was an interesting correlation between the metabolite groups, the bacterial genus groups and the key indicators. Myd88 and TNF- α -mRNA are the most explanatory variables in the case of probiotics reversing fluoride-induced intestinal damage (for Myd88, the genus: Mantel's $r = 0.63$; the metabolites: Mantel's $r = 0.59$; for TNF- α -mRNA, the genus: Mantel's $r = 0.60$ and the metabolites: Mantel's $r = 0.58$; all $p < 0.01$), with MDA and Occludin protein levels being the next most significant ($p < 0.01$). There was an expected correlation among the indicators of intestinal function. Furthermore, we conducted Spearman analysis to evaluate the correlations between each key factor in the metabolites, the genus and the intestinal

function indicators, separately. As shown in Figure 9B, among the 30 indicators related to the function of the ileum, seven key bacterial genera were correlated with at least sixteen of the indicators, while nine key metabolites were correlated with at least three of the indicators. The *Bifidobacterium*, MP3188 (ISO), MN18722 (OIC-7 α), and MP9998 (SIA) showed a closer correlation with more of the aforementioned experimental indicators. It is worth noting that Mantel and Spearman analyses indicate co-variation, not directionality.




Figure 8. The effects of fluoride exposure and GY007 intervention on the metabolic characteristics of ileum. (A–D) Principal component analysis (PCA) of Ctrl vs. F (A, POS, and B, NEG) and F+Bi vs. F (C, POS, and D, NEG). POS: positive ion mode; NEG: negative ion mode. (E) Venn diagram illustrating DEMs among experimental groups. (F–N) Expression of MN6249, MP3188, MN18188, MN18722, MP21633, MP22898, MN19753, MP26064, and MP9998 in the Ctrl, F, and F+Bi groups. The names of each metabolite are labeled in Table S4. (O,P) KEGG enrichment pathways of differentially expressed metabolomics between the Ctrl vs. F group and F vs. F+Bi group. $n = 8$. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 9. Correlation analysis of intestinal microbiota, metabolic activities and variables related to ileum function. **(A)** The identified key genus and metabolites of three groups of mice samples were related to each of 30 significantly differential ileum function indicators using Mantel test analysis. Edge width corresponds to the Mantel's r statistic for the corresponding distance correlations, and edge color denotes the statistical significance. Pairwise comparisons of intestinal functions are shown, with a color gradient denoting Pearson's correlation coefficient. **(B)** Spearman's rank correlation between the keystone genus, metabolites and biochemical indices, respectively. Rho in the color key showed Spearman rank correlation coefficient. * $p < 0.05$ and ** $p < 0.01$ denoted statistical significance between the correlations of keystone biomarkers and functional parameters.

4. Discussion

High fluoride-associated disorders constitute some of the most prevalent and severe endemic conditions worldwide, with particularly pronounced impacts on the gastrointestinal tract [14,65]. Consequently, strategies focused on mitigating fluoride-induced ileal injury have become a major area of research interest and significance. Probiotic-based interventions offer a promising approach to alleviating intestinal injury. The therapeutic effect of *B. animalis* subsp. *animalis* GY007 on high fluoride-induced intestinal damage in mice was evaluated. A review of the existing literature revealed the absence of a universally accepted standard for determining high fluoride exposure concentrations. The chosen dosage of 24 mg/kg body weight NaF and the duration were determined in accordance with our earlier investigations [14,22] and other published research [66–69]. According to the dose conversion formula of the U.S. Food and Drug Administration (FDA), the equivalent human dose is approximately 23.8 mg/L for an adult weighing 55 kg and with

a daily water intake of 4.5 L [20,70]. In contrast, the World Health Organization (WHO) recommends a guideline value for fluoride in drinking water of 1.5 mg/L, and the U.S. Environmental Protection Agency (EPA) primary maximum contaminant level (MCL) is 4.0 mg/L [71,72]. In practice, the primary strategy to mitigate fluoride-related health risks is to reduce fluoride intake [73]. Where low fluoride water or foods are not readily achievable, our findings suggest that GY007 could be explored as an adjunct, diet-deliverable approach to support intestinal barrier function during high fluoride exposure, rather than as a substitute for source control. *Bifidobacterium animalis* strains have been used as probiotic ingredients in foods and dietary supplements under FDA “no questions” GRAS notices [74], and they have also been officially included in the “List of Microorganisms Approved for Use in Food,” published by the National Health Commission (NHC), supporting their feasibility as a food ingredient [75]. Future work should include dose optimization and human studies in fluoride-exposed populations, incorporating clinically relevant outcomes (e.g., gastrointestinal symptoms and stool microbiome profiles).

Increased intestinal epithelial permeability is a critical determinant in the pathogenesis of various gastrointestinal disorders [76]. Tight junctions form the core structure of the selective permeability barrier between intestinal epithelial cells, consisting of tight junction proteins, including transmembrane components such as Claudin-1 and Occludin, and peripheral membrane-associated scaffold proteins such as ZO-1. Tight junction proteins create highly organized intercellular contacts through tight adhesion [77,78]. The disruption or loss of them leads to increased intestinal mucosal permeability, allowing the passage of pathogenic microorganisms and harmful substances, thereby triggering and exacerbating intestinal inflammation [79]. The data from this study demonstrated that fluoride exposure significantly elevated the blood levels of D-LA and DAO, resulting in increased intestinal epithelial permeability in mice. The mRNA expression and protein levels of the three tight junction proteins further confirmed the impairment of the intestinal barrier function in mice. Exposure to fluoride-containing drinking water has been shown to impair intestinal development across multiple segments and to suppress tight junction protein expression, thereby increasing mucosal permeability. Among the segments of the intestine, the ileum appears to experience the greatest adverse effects when exposed to fluoride [20,21]. Administration of GY007 at 1×10^9 CFU ameliorated the fluoride-induced increase in intestinal epithelial permeability, providing a robust basis for restoring intestinal barrier function.

Our recent study employed single-cell sequencing technology to investigate fluoride-induced damage to the ileum. The results showed that the expression of *Duox2* and *Duoxa2* in the ileal cells of fluoride-exposed mice was elevated, and the level of 4-HNE also increased [14]. Consistent with these observations, this study found that oxidative stress levels in the ileal tissues of mice exposed to a high fluoride exposure were elevated. *Duox2* is an epithelial antimicrobial dual oxidase, with *Duoxa2* serving as a key maturation factor for the enzyme. MacFie et al. [80] have reported that in individuals experiencing active ulcerative colitis, the mature *Duox2*–*Duoxa2* complex is the main enzyme system that generates reactive oxygen species (specifically hydrogen peroxide). Administration of GY007 permits the targeted modulation of these indices. Fluoride treatment decreased intestinal SOD and CAT and increased MDA in mice, which has been observed in both rat and chicken models [81,82]. Notably, fluoride exposure did not elicit a significant alteration in ileal glutathione (GSH) levels in the present study. This finding suggested that fluoride may exert a distinct pattern of oxidative stress injury in the ileum; however, additional evidence is required to substantiate this conclusion. While GY007 exhibited a partial reduction in H_2O_2 levels, its ability to fully alleviate oxidative stress remains limited, and further optimization of the GY007 administration protocol may enhance its efficacy. These findings suggest that GY007 could partially alleviate oxidative stress damage in the

ileum of mice caused by fluoride exposure, but further research is required to fully assess its potential.

Notably, some findings in this study differ from prior reports, particularly regarding Reg3b/Reg3g and ileal *Bifidobacterium* abundance. Previous work reported increased Reg3b/Reg3g expression and higher MUC2 and Ramp1 abundance in the ileum after chronic fluoride exposure, where a mouse model was exposed to drinking water fluoride at a concentration of 25/50 ppm for a duration of 56 weeks [14], whereas Reg3b/Reg3g showed an opposite trend in our gavage model (24 mg/kg NaF for 8 weeks). Fluoride exposure reduced ileal *Bifidobacterium* in the present study, whereas our earlier work in ICR mice using fluoride exposure via drinking water for 10 weeks showed an increase [20]. This discrepancy may be attributable to differences in the experimental animal, fluoride exposure paradigms, including the route of administration, and the duration of treatment. Reg3 proteins are thought to contribute to restoration and repair processes within the intestinal mucosa [80,83]. It exhibits antibacterial and anti-inflammatory activities, supports tissue regeneration, and contributes to the maintenance of intestinal homeostasis [84–87]. One study reported that mice lacking Reg3b exhibited exacerbated colitis manifestations relative to their wild-type counterparts [88]. The MUC2 gene encodes the predominant secreted mucin in the intestinal tract, constituting a major structural component of the mucus layer and acting as a critical contributor in protecting the ileal mucosa from infectious challenges [56]. When Ramp1 is lacking, animals exhibit heightened epithelial stress and become more vulnerable to infection by pathogenic bacteria [89,90]. Overall, our observations indicated that fluoride exposure disrupts intestinal mucosal homeostasis. Treatment with GY007 significantly reversed the changes in the indicators associated with ileal mucosal dysfunction induced by fluoride. The distinct Reg3a expression pattern may suggest a different regulatory response to GY007, which warrants further investigation. Future studies should investigate how GY007 modulates the regenerating gene family dynamics within the murine small intestine subjected to long-term fluoride exposure via drinking water. Elucidating whether the probiotic responses are tuned to specific physiological processes will provide a rationale for targeted investigations into probiotic engraftment and accumulation.

Increased intestinal permeability can activate pro-inflammatory signaling pathways, thereby contributing to the development of intestinal inflammation [54]. Consistent with this, fluoride exposure within this investigation increased ileal mRNA levels of *TNF- α* , *IL-6*, and *IFN- α* , whereas GY007 administration significantly downregulated the expression of pro-inflammatory mediators. Accumulating evidence indicates that probiotics can modulate inflammatory mediators. One study reported that a combined probiotic formulation comprising *Clostridium butyricum* and *Bifidobacterium infantis* ameliorated intestinal injury by normalizing IFN- γ , IL-10, and TNF- α levels [91]. *Streptococcus thermophiles* mitigated inflammatory responses by lowering TNF- α and enhancing IFN- γ and IL-10 [92]. Notably, fluoride exposure in the present study did not significantly alter IL-10 or IFN- γ levels. Although GY007 tended to attenuate the fluoride-associated increase in IL-17, this effect did not reach statistical significance ($p = 0.062$). TNF- α , IL-6, and IFN- α are downstream inflammatory mediators of Toll-like receptor (TLR) signaling (Figure S1). TLRs are pattern recognition receptors and are essential mediators of immune activity at mucosal surfaces [93]. Further detection of the key mediators on the TLR pathway revealed that fluoride significantly increased the levels of IRF7, IRAK4, Myd88, and NF- κ B, while GY007 could reverse this trend. During the process of fluoride damage, only TLR9 and TLR4 showed significant changes, while GY007 only had an effect on TLR9. Situated within endosomal compartments, TLR9 acts as a specialized DNA sensor by detecting CpG dinucleotide motifs that are unmethylated or only minimally methylated, including those in

immune complexes [94], and subsequently leads to the engagement of Myd88 [95]. As a pivotal adaptor in the TLR9 signaling cascade, Myd88 facilitates NF- κ B phosphorylation and activation by recruiting members of the interleukin-1 receptor-associated kinase (IRAK) family. Upon activation, NF- κ B translocates to the cell nucleus, where it induces the transcription of multiple pro-inflammatory cytokines and co-stimulatory molecules, culminating in tissue injury [96]. Overall, these data suggest that the key components of the Toll-like receptor signaling pathway may be involved in the modulation of immune homeostasis in the ileum of mice by the intervention with GY007. Future investigations should conduct further research in relevant areas to clarify the mechanism of the effects of probiotics.

The small intestine not only acts as a barrier but also provides a living environment for microorganisms [56]. On the basis of the AB/PAS staining results, we subsequently performed a more detailed analysis of the intestinal microbial community. The findings indicated that probiotic intervention restored fluoride-disrupted gut microbiota diversity, as shown by the rebound in the reduced Simpson and Shannon indices and the normalization of community composition and structure. We conducted a comparative analysis between groups to further assess the variation in *Bifidobacterium* levels across the different treatment cohorts. Notably, both LEfSe and machine learning analyses identified *Bifidobacterium* as a discriminative biomarker; moreover, it exhibited the highest feature importance score in the machine learning model, further underscoring the role of *Bifidobacterium animalis* subsp. *animalis* GY007 in modulating and maintaining gut microbial homeostasis. Administration of GY007 was associated with an enrichment of intestinal *Bifidobacterium* and *Dubosiella*, accompanied by a decrease in *Paramuribaculum* and *Kineothrix* et al. *Bifidobacteria* are well-established probiotics recognized for their beneficial effects on gut health. Compared with *Akkermansia muciniphila*, *Dubosiella* has been reported to exhibit stronger probiotic efficacy, providing greater protection against colonic mucosal barrier injury and attenuating intestinal inflammation [97]. *Kineothrix* is positively correlated with intestinal inflammation [98], while *Paramuribaculum* is regarded as a potential pathogenic bacterium associated with inflammatory bowel disease (IBD) [99]. GY007 may facilitate intestinal repair by modulating the microbiota environment, as reflected by the enrichment of advantageous taxa alongside a decline in potentially pathogenic bacterial groups.

The untargeted metabolomics analysis identified a total of 48 metabolites present in both comparisons. For example, the F group showed elevated levels of HIA and ISO, whereas both metabolites were markedly lower in the F+Bi group; conversely, GLA, SAB, and SIA were diminished under fluoride exposure but became significantly more abundant following administration with GY007. HIA is a benzoic acid-related compound and ranks among the predominant organic acids detected in mammalian urine, functioning as an important co-metabolite that links microbial activity in the gut with host metabolism [100,101]. Ni et al. demonstrated that the gut microbiota-mediated and host-dependent accumulation of hippuric acid results in an increase in reactive oxygen species (ROS) levels [58]. Evidence from both animal models and cell-based systems indicates that GLA contributes to preserving gut homeostasis while regulating the abundance of proteins involved in tight junction architecture, cell adhesion, and focal adhesion assemblies [102–104]. The selection of ISO (MP3188), OIC-7 α (MN18722), and SIA (MP9998) was based on their observed correlations with multiple ileal injury indicators across the experimental groups. ISO, a nucleobase derivative, may reflect altered microbial nucleotide metabolism [105], while OIC-7 α , a bile acid biosynthesis intermediate, is implicated in regulating intestinal barrier integrity and inflammation pathways through receptors like FXR [106,107]. SIA, a phenolic compound, is known for its antioxidant and anti-inflammatory effects, which contribute to reducing intestinal inflammation [63,108–110]. Furthermore, we performed KEGG pathway

analysis on the metabolites showing differential abundance. The histidine metabolism signaling pathway was simultaneously observed in both the Ctrl vs. F comparison and the F vs. F+Bi comparison, and it holds significant importance. The metabolic process of histidine (HIS) is closely associated with the intestinal microbial community and appears to be an important determinant of the onset and worsening of chronic disorders [111]. Among human proteins, HIS contains the smallest proportion of essential amino acids. Variations in its abundance, as well as exogenous supplementation, have been linked to multiple potential health-promoting effects, notably antioxidant activity and attenuation of inflammatory responses [112,113]. However, excessive intake of HIS may elicit detrimental outcomes, including cell apoptosis and increased tissue damage [114]. This indicated the importance of maintaining a stable state rather than simply increasing or decreasing the levels of substances. Subsequently, we conducted a comprehensive analysis of the combined indicators of the microbial community, metabolic community, and intestinal function. There were correlations between the microbial community, metabolic community and the intestinal function indicators after the GY007 intervention. Further detailed analysis revealed that the *Bifidobacterium* was associated with each of these indicators. Among the several metabolites of concern, the prioritized metabolites, ISO, OIC 7 α , and SIA, emphasized the integrative metabolic shifts that may explain the therapeutic effects of GY007 in alleviating fluoride-induced damage. The above results further demonstrate the significance of the *Bifidobacterium animalis* subsp. *animalis* GY007 and the substances that we need to pay attention to particularly.

Although this study has demonstrated the therapeutic efficacy of GY007 in alleviating fluoride-induced ileal injury, certain limitations remain. Firstly, the analysis was limited to the ileum, a specific segment of the intestine, and therefore the findings may not be generalizable to the entire gastrointestinal system. Additional studies are warranted to evaluate the impact of GY007 on other regions of the intestine. Secondly, although the 24 mg/kg body weight dosage of sodium fluoride over 8 weeks induced significant toxic effects on the murine ileum in the present study, future research should include preliminary toxicity assessments of sodium fluoride following established toxicity guidelines. Thirdly, additional investigation is required to clarify whether GY007 alleviates damage to the ileum through a primary mechanism acting on the tissue itself, or instead via secondary pathways that mediate the observed protective outcome. This could be explored through future experiments involving antibiotic-induced perturbation of the gut microbiota.

5. Conclusions

The investigation demonstrated that *B. animalis* subsp. *animalis* GY007 as a potential probiotic strain could mitigate the ileal injury and restore the microbiota–metabolite balance disrupted by high fluoride exposure. Its principal functions include maintaining the integrity of the ileal epithelial barrier and associated mucosal functions, modulating antioxidant capacity, and influencing inflammatory mediators potentially linked to the TLR9/NF- κ B/IRF7 signaling pathway, as well as restoring the dysbiosis of both the microbiota and metabolome. Microbial analysis further highlighted the role of *Bifidobacterium animalis* in this process. Metabolic analysis identified ISO, OIC-7 α , and SIA as key metabolites (Figure 10). However, the underlying mechanism remains incompletely understood, and further studies are needed to explore this aspect. Future work should employ causality-oriented approaches, such as targeted microbiota/metabolite depletion or modulation. In summary, this research identified a probiotic that could mitigate ileal injury caused by high fluoride exposure, providing valuable insights for developing therapeutic strategies to alleviate the biological harm associated with environmental fluoride pollution. Moreover,

our findings offer an integrative perspective on microbiota–host interactions in the context of fluoride exposure.




Figure 10. Summary of the effects of GY007 on fluoride-induced ileal injury. This figure highlights the restoration of microbiota balance, reduction in inflammation and oxidative stress, and improvement of intestinal barrier function through GY007 treatment.

Supplementary Materials: The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/biology15050402/s1>, Figure S1: Display of Toll-like receptor signaling pathway; Figure S2: Evaluation of TLR signaling molecule levels in mice; Figure S3: Evaluation of the intestinal community in mice; Figure S4: Evaluation of intestinal metabolites in mice; Table S1: Primer sequences for RT-qPCR experiment; Table S2: Differentially abundant metabolites between Ctrl and F; Table S3: Differentially abundant metabolites between F and F+Bi; Table S4: Metabolite names; File S1: Materials and Methods.

Author Contributions: Y.C.: Formal analysis, Data curation, Writing—original draft. Y.Z., B.J. and D.Z.: Writing—review and editing. X.N.: Funding acquisition, Methodology, Project administration. All authors have read and agreed to the published version of the manuscript.

Funding: Sichuan Science & Technology Project (2025YFHZ0278).

Institutional Review Board Statement: All animal experiment procedures were conducted in accordance with the guidelines of the Animal Welfare Act and all procedures and protocols were approved by the Sichuan Agricultural University Animal Ethical and Welfare Committee (approval number: 20250405; experimental animal license number: SYXKchuan2024-0187).

Informed Consent Statement: Not applicable.

Data Availability Statement: The 16S rRNA sequencing data of ileum in this study have been deposited in the Genome Sequence Archive database (<https://ngdc.cnca.ac.cn/gsa/s/88XV5479>, accessed on 3 February 2026) under accession number PRJCA049428.

Acknowledgments: We express our gratitude to every author and to all those who contributed to the experiment. We would like to express our special thanks to Baoping Gan, Dandan Wang, Lixiao Duan, and Kangcheng Pan for their contributions in this regard.

Conflicts of Interest: All authors consent to the publication of this work. The authors declare no competing interests.

References

1. Liang, C.; Zhuang, C.; Cheng, C.; Bai, J.; Wu, Y.; Li, X.; Yang, J.; Li, B.; Fu, W.; Zhu, Q.; et al. Fluoride induces hepatointestinal damage and vitamin B(2) mitigation by regulating IL-17A and *Bifidobacterium* in ileum. *J. Adv. Res.* **2025**, *72*, 671–684. [\[CrossRef\]](#)
2. Skórka-Majewicz, M.; Goschorska, M.; Żwierzeło, W.; Baranowska-Bosiacka, I.; Styburski, D.; Kapczuk, P.; Gutowska, I. Effect of fluoride on endocrine tissues and their secretory functions—Review. *Chemosphere* **2020**, *260*, 127565. [\[CrossRef\]](#)
3. Podgorski, J.; Berg, M. Global analysis and prediction of fluoride in groundwater. *Nat. Commun.* **2022**, *13*, 4232. [\[CrossRef\]](#)
4. Johnston, N.R.; Strobel, S.A. Principles of fluoride toxicity and the cellular response: A review. *Arch. Toxicol.* **2020**, *94*, 1051–1069. [\[CrossRef\]](#)
5. Ahmad Dar, F.; Kurella, S. Fluoride in drinking water: An in-depth analysis of its prevalence, health effects, advances in detection and treatment. *Mater. Today* **2024**, *102*, 349–360. [\[CrossRef\]](#)
6. Wang, F.; Li, Y.; Tang, D.; Zhao, J.; Yang, X.; Liu, Y.; Peng, F.; Shu, L.; Wang, J.; He, Z.; et al. Effects of water improvement and defluoridation on fluorosis-endemic areas in China: A meta-analysis. *Environ. Pollut.* **2021**, *270*, 116227. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Andezhath, S.K.; Ghosh, G. Fluorosis management in India: The impact due to networking between health and rural drinking water supply agencies. *Int. Assoc. Hydrol. Sci.* **2000**, *1*, 159–165.
8. Xin, J.; Zhu, B.; Wang, H.; Zhang, Y.; Sun, N.; Cao, X.; Zheng, L.; Zhou, Y.; Fang, J.; Jing, B.; et al. Prolonged fluoride exposure induces spatial-memory deficit and hippocampal dysfunction by inhibiting small heat shock protein 22 in mice. *J. Hazard. Mater.* **2023**, *456*, 131595. [\[CrossRef\]](#)
9. Dec, K.; Lukomska, A.; Baranowska-Bosiacka, I.; Pilutin, A.; Maciejewska, D.; Skonieczna-Żydecka, K.; Derkacz, R.; Goschorska, M.; Wąsik, A.; Rębacz-Marón, E.; et al. Pre-and postnatal exposition to fluorides induce changes in rats liver morphology by impairment of antioxidant defense mechanisms and COX induction. *Chemosphere* **2018**, *211*, 112–119. [\[CrossRef\]](#)
10. Acharyya, A. The economic cost of fluoride contamination in groundwater: A case study from birbhum district of West Bengal. In *Ground Water Contamination in India: Adverse Effects on Habitats*; Springer: Berlin/Heidelberg, Germany, 2024; pp. 257–273.
11. Indu, R.; Krishnan, S.; Shah, T. Impacts of groundwater contamination with fluoride and arsenic affliction severity, medical cost and wage loss in some villages of India. *Int. J. Rural. Manag.* **2007**, *3*, 69–93. [\[CrossRef\]](#)
12. Lacson, C.F.Z.; Lu, M.C.; Huang, Y.H. Fluoride network and circular economy as potential model for sustainable development—a review. *Chemosphere* **2020**, *239*, 124662. [\[CrossRef\]](#)
13. Yin, N.; Li, Y.; Yang, Y.; Fan, C.; Li, Y.; Du, X.; Sun, G.; Cui, Y. Human health risk assessment in aluminium smelting site: Soil fluoride bioaccessibility and relevant mechanism in simulated gastrointestinal tract. *J. Hazard. Mater.* **2021**, *416*, 125899. [\[CrossRef\]](#)
14. Xin, J.; Chen, Y.; Huang, Y.; Sun, N.; Peng, W.; Lai, C.; Yang, R.; Chen, W.; Duan, L.; Wang, D.; et al. Single-cell RNA sequencing uncovers intestinal immune alterations and cellular diversity from chronic fluoride exposure in mice. *Theranostics* **2025**, *15*, 7242–7269. [\[CrossRef\]](#)
15. Fu, R.; Niu, R.; Zhao, F.; Wang, J.; Cao, Q.; Yu, Y.; Liu, C.; Zhang, D.; Sun, Z. Exercise alleviated intestinal damage and microbial disturbances in mice exposed to fluoride. *Chemosphere* **2022**, *288*, 132658. [\[CrossRef\]](#)
16. Li, A.; Wang, Y.; He, Y.; Liu, B.; Iqbal, M.; Mehmood, K.; Jamil, T.; Chang, Y.F.; Hu, L.; Li, Y.; et al. Environmental fluoride exposure disrupts the intestinal structure and gut microbial composition in ducks. *Chemosphere* **2021**, *277*, 130222. [\[CrossRef\]](#)
17. Dionizio, A.; Melo, C.G.S.; Sabino-Arias, I.T.; Araujo, T.T.; Ventura, T.M.O.; Leite, A.L.; Souza, S.R.G.; Santos, E.X.; Heubel, A.D.; Souza, J.G.; et al. Effects of acute fluoride exposure on the jejunum and ileum of rats: Insights from proteomic and enteric innervation analysis. *Sci. Total Environ.* **2020**, *741*, 140419. [\[CrossRef\]](#)
18. Li, M.; Wang, J.; Wu, P.; Manthari, R.K.; Zhao, Y.; Li, W.; Wang, J. Self-recovery study of the adverse effects of fluoride on small intestine: Involvement of pyroptosis induced inflammation. *Sci. Total Environ.* **2020**, *742*, 140533. [\[CrossRef\]](#)
19. Zhang, S.; Zhao, T.; Wang, Y.; Mi, J.; Liu, J.; Fan, X.; Niu, R.; Sun, Z. Intestinal microbiota regulates colonic inflammation in fluorosis mice by TLR/NF- κ b pathway through short-chain fatty acids. *Food Chem. Toxicol.* **2023**, *178*, 113866. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Xin, J.; Wang, H.; Sun, N.; Bughio, S.; Zeng, D.; Li, L.; Wang, Y.; Khalique, A.; Zeng, Y.; Pan, K.; et al. Probiotic alleviate fluoride-induced memory impairment by reconstructing gut microbiota in mice. *Ecotoxicol. Environ. Saf.* **2021**, *215*, 112108. [\[CrossRef\]](#) [\[PubMed\]](#)
21. Xin, J.; Zeng, D.; Wang, H.; Sun, N.; Khalique, A.; Zhao, Y.; Wu, L.; Pan, K.; Jing, B.; Ni, X. *Lactobacillus johnsonii* BS15 improves intestinal environment against fluoride-induced memory impairment in mice—A study based on the gut-brain axis hypothesis. *PeerJ* **2020**, *8*, e10125. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Huang, H.; Lin, Y.; Xin, J.; Sun, N.; Zhao, Z.; Wang, H.; Duan, L.; Zhou, Y.; Liu, X.; Fang, J.; et al. Fluoride exposure-induced gut microbiota alteration mediates colonic ferroptosis through N(6)-methyladenosine (m(6)A) mediated silencing of SLC7A11. *Ecotoxicol. Environ. Saf.* **2024**, *283*, 116816. [\[CrossRef\]](#)

23. Pillai, P.; Dharaskar, S.; Pandian, S.; Panchal, H.J.E.T. Overview of fluoride removal from water using separation techniques. *Environ. Technol. Innov.* **2020**, *21*, 101246. [[CrossRef](#)]
24. Karunanithi, M.; Agrawal, R.; Qanungo, K. A review of fluoride removal from ground water by various adsorption techniques. *J. Chil. Chem. Soc.* **2023**, *68*, 5839–5846. [[CrossRef](#)]
25. World Health Organization. *Fluoride in Drinking-Water: Background Document for Development of WHO Guidelines for Drinking-Water Quality*; WHO/SDE/WSH/03.04/96; World Health Organization: Geneva, Switzerland, 2004.
26. Oner, A.C.; Dede, S.; Yur, F.; Oner, A.J.F. The effect of vitamin C and vitamin E on DNA damage, oxidative status, and some biochemical parameters in rats with experimental fluorosis. *Fluoride* **2020**, *53*, 154–163.
27. Kumar, N.; Sood, S.; Arora, B.; Singh, M.; Roy, P.S. To study the effect of Vitamin D and E on sodium-fluoride-induced toxicity in reproductive functions of male rabbits. *Toxicol. Int.* **2012**, *19*, 182–187. [[CrossRef](#)]
28. Miao, K.; Zhang, L.; Yang, S.; Qian, W.; Zhang, Z. Intervention of selenium on apoptosis and Fas/FasL expressions in the liver of fluoride-exposed rats. *Environ. Toxicol. Pharmacol.* **2013**, *36*, 913–920. [[CrossRef](#)] [[PubMed](#)]
29. Kravchenko, J.; Rango, T.; Akushevich, I.; Atlaw, B.; McCornick, P.G.; Merola, R.B.; Paul, C.; Weinthal, E.; Harrison, C.; Vengosh, A.; et al. The effect of non-fluoride factors on risk of dental fluorosis: Evidence from rural populations of the Main Ethiopian Rift. *Sci. Total Environ.* **2014**, *488–489*, 595–606. [[CrossRef](#)] [[PubMed](#)]
30. Rocha, R.A.; de la Fuente, B.; Clemente, M.J.; Ruiz, A.; Vélez, D.; Devesa, V. Factors affecting the bioaccessibility of fluoride from seafood products. *Food Chem. Toxicol.* **2013**, *59*, 104–110. [[CrossRef](#)] [[PubMed](#)]
31. Wang, J.; Yang, J.; Cheng, X.; Xiao, R.; Zhao, Y.; Xu, H.; Zhu, Y.; Yan, Z.; Ommati, M.M.; Manthari, R.K.; et al. Calcium alleviates fluoride-induced bone damage by inhibiting endoplasmic reticulum stress and mitochondrial dysfunction. *J. Agric. Food Chem.* **2019**, *67*, 10832–10843. [[CrossRef](#)]
32. Hill, C.; Guarner, F.; Reid, G.; Gibson, G.R.; Merenstein, D.J.; Pot, B.; Morelli, L.; Canani, R.B.; Flint, H.J.; Salminen, S.; et al. Expert consensus document: The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* **2014**, *11*, 506–514. [[CrossRef](#)]
33. Malyoth, G.; Bauer, A. Observations on *Bacterium bifidum*. *Z. Kinderheilkd.* **1950**, *68*, 358–367. [[CrossRef](#)] [[PubMed](#)]
34. Turrone, F.; Foroni, E.; Pizzetti, P.; Giubellini, V.; Ribbera, A.; Merusi, P.; Cagnasso, P.; Bizzarri, B.; de'Angelis, G.L.; Shanahan, F.; et al. Exploring the diversity of the bifidobacterial population in the human intestinal tract. *Appl. Environ. Microbiol.* **2009**, *75*, 1534–1545. [[CrossRef](#)]
35. Mianzhi, Y.; Shah, N.P. Contemporary nucleic acid-based molecular techniques for detection, identification, and characterization of *Bifidobacterium*. *Crit. Rev. Food Sci. Nutr.* **2017**, *57*, 987–1016. [[CrossRef](#)]
36. Shadnoush, M.; Shaker Hosseini, R.; Mehrabi, Y.; Delpisheh, A.; Alipoor, E.; Faghfoori, Z.; Mohammadpour, N.; Zaringhalam Moghadam, J. Probiotic yogurt affects pro- and anti-inflammatory factors in patients with inflammatory bowel disease. *Iran. J. Pharm. Res.* **2013**, *12*, 929–936.
37. Logan, A.C.; Katzman, M. Major depressive disorder: Probiotics may be an adjuvant therapy. *Med. Hypotheses* **2005**, *64*, 533–538. [[CrossRef](#)] [[PubMed](#)]
38. Xie, Y.; Guo, Q.; Li, S.; Liu, M.; Zhang, Q.; Xu, Z.; Sun, H. Anti-inflammatory properties of *Bifidobacterium longum* expressing human manganese superoxide dismutase using the TNBS-induced rats model of colitis. *J. Microbiol. Biotechnol.* **2017**, *1*, 27.
39. Chae, J.M.; Heo, W.; Cho, H.T.; Lee, D.H.; Kim, J.H.; Rhee, M.S.; Park, T.S.; Kim, Y.K.; Lee, J.H.; Kim, Y.J. Effects of orally-administered *Bifidobacterium animalis* subsp. *lactis* strain BB12 on dextran sodium sulfate-induced colitis in mice. *J. Microbiol. Biotechnol.* **2018**, *28*, 1800–1805. [[CrossRef](#)]
40. Li, H.; Zhang, L.; Li, J.; Wu, Q.; Qian, L.; He, J.; Ni, Y.; Kovatcheva-Datchary, P.; Yuan, R.; Liu, S.; et al. Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota. *Nat. Metab.* **2024**, *6*, 578–597. [[CrossRef](#)]
41. Wang, Y.; Wang, Y.; Ding, K.; Liu, Y.; Liu, D.; Chen, W.; Zhang, X.; Luo, C.; Zhang, H.; Xu, T.; et al. Effectiveness of Psychobiotic *Bifidobacterium breve* BB05 in managing psychosomatic diarrhea in college students by regulating gut microbiota: A randomized, double-blind, placebo-controlled trial. *Nutrients* **2024**, *16*, 1989. [[CrossRef](#)]
42. Xin, J.; Zeng, D.; Wang, H.; Sun, N.; Zhao, Y.; Dan, Y.; Pan, K.; Jing, B.; Ni, X. Probiotic *Lactobacillus johnsonii* BS15 promotes growth performance, intestinal immunity, and gut microbiota in piglets. *Probiotics Antimicrob. Proteins* **2020**, *12*, 184–193. [[CrossRef](#)] [[PubMed](#)]
43. Gan, B.; Zhang, X.; Xin, J.; Duan, L.; Sun, N.; Chen, Y.; Zeng, J.; Lian, Y.; Li, H.; Wang, H.; et al. *Lactobacillus johnsonii* HL79 mitigate plateau environment-induced hippocampal dysfunction in mice. *AMB Express* **2025**, *15*, 96. [[CrossRef](#)]
44. Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith, G.A.; Alexander, H.; Alm, E.J.; Arumugam, M.; Asnicar, F.; et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* **2019**, *37*, 852–857. [[CrossRef](#)]
45. Callahan, B.J.; McMurdie, P.J.; Rosen, M.J.; Han, A.W.; Johnson, A.J.; Holmes, S.P. DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* **2016**, *13*, 581–583. [[CrossRef](#)] [[PubMed](#)]

46. Katoh, K.; Misawa, K.; Kuma, K.; Miyata, T. MAFFT: A novel method for rapid multiple sequence alignment based on fast fourier transform. *Nucleic Acids Res.* **2002**, *30*, 3059–3066. [[CrossRef](#)] [[PubMed](#)]
47. Price, M.N.; Dehal, P.S.; Arkin, A.P. FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix. *Mol. Biol. Evol.* **2009**, *26*, 1641–1650. [[CrossRef](#)]
48. McDonald, D.; Jiang, Y.; Balaban, M.; Cantrell, K.; Zhu, Q.; Gonzalez, A.; Morton, J.T.; Nicolaou, G.; Parks, D.H.; Karst, S.M.; et al. Greengenes2 unifies microbial data in a single reference tree. *Nat. Biotechnol.* **2024**, *42*, 715–718. [[CrossRef](#)] [[PubMed](#)]
49. Bokulich, N.A.; Kaehler, B.D.; Rideout, J.R.; Dillon, M.; Bolyen, E.; Knight, R.; Huttley, G.A.; Gregory Caporaso, J. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2's q2-feature-classifier plugin. *Microbiome* **2018**, *6*, 90. [[CrossRef](#)]
50. Bray, J.R.; Curtis, J.T. An ordination of the upland forest communities of southern wisconsin. *Ecol. Monogr.* **1957**, *27*, 326–349. [[CrossRef](#)]
51. McArdle, B.H.; Anderson, M.J. Fitting multivariate models to community data: A comment on distance-based redundancy analysis. *Ecology* **2001**, *82*, 290–297. [[CrossRef](#)]
52. Breiman, L. Random forests. *Mach. Learn.* **2001**, *45*, 5–32. [[CrossRef](#)]
53. Liaw, A.; Wiener, M. Classification and regression by randomForest. *R News* **2002**, *2*, 18–22.
54. Xiong, L.; Diwakarla, S.; Chatzis, R.; Artaiz, O.; Macowan, M.; Zhang, S.; Garnham, A.; Morgan, P.K.; Mellett, N.A.; Meikle, P.J.; et al. Acute exposure to high-fat diet impairs ILC3 functions and gut homeostasis. *Immunity* **2025**, *58*, 1185–1200. [[CrossRef](#)]
55. Hansson, G.C. Mucins and the Microbiome. *Annu. Rev. Biochem.* **2020**, *89*, 769–793. [[CrossRef](#)]
56. Birchenough, G.M.H.; Schroeder, B.O.; Sharba, S.; Arike, L.; Recktenwald, C.V.; Puértolas-Balint, F.; Subramani, M.V.; Hansson, K.T.; Yilmaz, B.; Lindén, S.K.; et al. Muc2-dependent microbial colonization of the jejunal mucus layer is diet sensitive and confers local resistance to enteric pathogen infection. *Cell Rep.* **2023**, *42*, 112084. [[CrossRef](#)] [[PubMed](#)]
57. Kaur, H.; Ali, S.A. Probiotics and gut microbiota: Mechanistic insights into gut immune homeostasis through TLR pathway regulation. *Food Funct.* **2022**, *13*, 7423–7447. [[CrossRef](#)] [[PubMed](#)]
58. Ni, Q.; Xia, L.; Huang, Y.; Yuan, X.; Gu, W.; Chen, Y.; Wang, Y.; Nian, M.; Wu, S.; Cai, H.; et al. Gut microbiota dysbiosis orchestrates vitiligo-related oxidative stress through the metabolite hippuric acid. *Microbiome* **2025**, *13*, 112. [[CrossRef](#)]
59. Chrysostomou, D.; Roberts, L.A.; Marchesi, J.R.; Kinross, J.M. Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy. *Gastroenterology* **2023**, *164*, 198–213. [[CrossRef](#)]
60. Wu, Y.; Cheng, A.; Wang, Y.; Zhu, Q.; Ren, X.; Lu, Y.; Shi, E.; Zhuang, C.; Wang, J.; Liang, C.; et al. *Bifidobacterium* relieved fluoride-induced hepatic and ileal toxicity via inflammatory response and bile acid transporters in mice. *Foods* **2024**, *13*, 1011. [[CrossRef](#)] [[PubMed](#)]
61. Peng, X.; Zhong, R.; Dong, S.; Qiu, Y.; Shu, G.; Huang, S.; Liu, T.; Yang, Y.; Zhang, B. 18 β -Glycyrrhetic acid from glycyrrhiza uralensis protects colonic epithelium in ulcerative colitis by activating Wnt/ β -catenin pathway to restore tight junction. *Phytomedicine* **2025**, *143*, 156830. [[CrossRef](#)]
62. Yang, X.; Yang, J.; Wang, A.; Zheng, Y.; Lin, J.; Kong, Z.; Tian, Y.; Dong, H.; Zhang, Z.; Song, R. Saikosaponin a ameliorates ulcerative colitis by targeting the CH₂₅H/25-OHC axis to inhibit NLRP3 inflammasome in macrophages. *Phytomedicine* **2025**, *143*, 156844. [[CrossRef](#)]
63. Lee, J.Y. Anti-inflammatory effects of sinapic acid on 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. *Arch. Pharmacol. Res.* **2018**, *41*, 243–250. [[CrossRef](#)]
64. Ning, L.; Zhou, Y.L.; Sun, H.; Zhang, Y.; Shen, C.; Wang, Z.; Xuan, B.; Zhao, Y.; Ma, Y.; Yan, Y.; et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. *Nat. Commun.* **2023**, *14*, 7135. [[CrossRef](#)] [[PubMed](#)]
65. Cao, W.; Zhang, Z.; Guo, H.; Fu, Y.; Gao, Z.; Nan, T.; Ren, Y.; Li, Z. Spatial distribution and controlling mechanisms of high fluoride groundwater in the coastal plain of Bohai Rim, North China. *J. Hydrol.* **2023**, *617*, 128952. [[CrossRef](#)]
66. Wang, J.; Yue, B.; Zhang, X.; Guo, X.; Sun, Z.; Niu, R. Effect of exercise on microglial activation and transcriptome of hippocampus in fluorosis mice. *Sci. Total Environ.* **2021**, *760*, 143376. [[CrossRef](#)]
67. Kuang, P.; Cui, H.; Yu, L. Sodium fluoride suppresses spleen development through MAPK/ERK signaling pathway in mice. *Ecotoxicol. Environ. Saf.* **2022**, *241*, 113764. [[CrossRef](#)]
68. Lu, Y.; Luo, Q.; Cui, H.; Deng, H.; Kuang, P.; Liu, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; et al. Sodium fluoride causes oxidative stress and apoptosis in the mouse liver. *Aging* **2017**, *9*, 1623–1639. [[CrossRef](#)] [[PubMed](#)]
69. Kuang, P.; Deng, H.; Liu, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Sodium fluoride induces splenocyte autophagy via the mammalian targets of rapamycin (mTOR) signaling pathway in growing mice. *Aging* **2018**, *10*, 1649–1665. [[CrossRef](#)]

70. U.S. Food and Drug Administration. *Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers*; CDER: Washington, DC, USA, 2005. Available online: <https://www.fda.gov/media/72309/download> (accessed on 21 January 2026).
71. World Health Organization. *Guidelines for Drinking-Water Quality*, 4th ed.; World Health Organization: Geneva, Switzerland, 2011. Available online: <https://www.who.int/publications/i/item/9789241548151> (accessed on 21 January 2026).
72. U.S. Environmental Protection Agency (EPA). Fluoride in Drinking Water. Available online: <https://www.epa.gov/sdwa/fluoride-drinking-water> (accessed on 27 January 2026).
73. World Health Organization. *Inadequate or Excess Fluoride: A Major Public Health Concern*; World Health Organization: Geneva, Switzerland, 2019. Available online: <https://www.who.int/teams/environment-climate-change-and-health/chemical-safety-and-health/health-impacts/chemicals/inadequate-or-excess-fluoride> (accessed on 28 January 2026).
74. U.S. Food and Drug Administration. GRAS Notice Inventory, GRN No. 1239: *Bifidobacterium animalis* subsp. *lactis* PTA-126817; FDA GRAS Notice Database. Available online: <https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=1239&set=GRASNotices> (accessed on 28 January 2026).
75. National Health Commission of the People's Republic of China. *Interpretation of the Updated "Lists of Microorganisms Permitted for Use in Food and in Infant Foods"* (Announcement No. 4, 2022); National Health Commission: Beijing, China, 2022. Available online: <https://www.nhc.gov.cn/sps/c100087/202208/9e1dfdedbc0143879284dae3f9367478.shtml> (accessed on 28 January 2026).
76. Xu, B.; Liang, S.; Zhao, J.; Li, X.; Guo, J.; Xin, B.; Li, B.; Huo, G.; Ma, W. *Bifidobacterium animalis* subsp. *lactis* XLTG11 improves antibiotic-related diarrhea by alleviating inflammation, enhancing intestinal barrier function and regulating intestinal flora. *Food Funct.* **2022**, *13*, 6404–6418. [CrossRef] [PubMed]
77. Odenwald, M.A.; Turner, J.R. The intestinal epithelial barrier: A therapeutic target? *Nat. Rev. Gastroenterol. Hepatol.* **2017**, *14*, 9–21. [CrossRef]
78. Farquhar, M.G.; Palade, G.E. Junctional complexes in various epithelia. *J. Cell Biol.* **1963**, *17*, 375–412. [CrossRef]
79. Su, L.; Shen, L.; Clayburgh, D.R.; Nalle, S.C.; Sullivan, E.A.; Meddings, J.B.; Abraham, C.; Turner, J.R. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. *Gastroenterology* **2009**, *136*, 551–563. [CrossRef]
80. MacFie, T.S.; Poulsom, R.; Parker, A.; Warnes, G.; Boitsova, T.; Nijhuis, A.; Suraweera, N.; Poehlmann, A.; Szary, J.; Feakins, R.; et al. Duox2 and Duoxa2 form the predominant enzyme system capable of producing the reactive oxygen species H₂O₂ in active ulcerative colitis and are modulated by 5-aminosalicylic acid. *Inflamm. Bowel Dis.* **2014**, *20*, 514–524. [CrossRef]
81. Komuroglu, A.U.; Seckin, H.; Ertas, M.; Meydan, I. Metagenomic analysis of intestinal microbiota in florated rats. *Biol. Trace Elem. Res.* **2022**, *200*, 3275–3283. [CrossRef]
82. Luo, Q.; Cui, H.; Peng, X.; Fang, J.; Huang, J.J.F. Intestinal oxidative stress in broilers caused by high dietary fluorine. *Fluoride* **2012**, *45*, 349–356.
83. Shindo, R.; Katagiri, T.; Komazawa-Sakon, S.; Ohmuraya, M.; Takeda, W.; Nakagawa, Y.; Nakagata, N.; Sakuma, T.; Yamamoto, T.; Nishiyama, C.; et al. Regenerating islet-derived protein (Reg)3 β plays a crucial role in attenuation of ileitis and colitis in mice. *Biochem. Biophys. Res.* **2020**, *21*, 100738. [CrossRef] [PubMed]
84. Mao, H.; Jia, J.; Sheng, J.; Zhang, S.; Huang, K.; Li, H.; He, F. Protective and anti-inflammatory role of reg1a in inflammatory bowel disease induced by JAK/STAT3 signaling axis. *Int. Immunopharmacol.* **2021**, *92*, 107304. [CrossRef] [PubMed]
85. Chen, W.; Imasaka, M.; Lee, M.; Fukui, H.; Nishiura, H.; Ohmuraya, M. Reg family proteins contribute to inflammation and pancreatic stellate cells activation in chronic pancreatitis. *Sci. Rep.* **2023**, *13*, 12201. [CrossRef] [PubMed]
86. Sun, C.; Wang, X.; Hui, Y.; Fukui, H.; Wang, B.; Miwa, H. The potential role of reg family proteins in inflammatory and inflammation-associated diseases of the gastrointestinal tract. *Int. J. Mol. Sci.* **2021**, *22*, 7196. [CrossRef]
87. Edwards, J.A.; Tan, N.; Toussaint, N.; Ou, P.; Mueller, C.; Stanek, A.; Zinsou, V.; Roudnitsky, S.; Sagal, M.; Dresner, L.; et al. Role of regenerating islet-derived proteins in inflammatory bowel disease. *World J. Gastroenterol.* **2020**, *26*, 2702–2714. [CrossRef]
88. Wang, J.; Chen, W.; Wang, Y.; Hayakawa, E.; Nishiura, H.; Ohmuraya, M. Effects of the regenerating gene family on dss-induced ulcerative colitis in a mouse model. *Biochem. Biophys. Res. Commun.* **2025**, *766*, 151894. [CrossRef]
89. Yang, D.; Jacobson, A.; Meerschaert, K.A.; Sifakis, J.J.; Wu, M.; Chen, X.; Yang, T.; Zhou, Y.; Anekal, P.V.; Rucker, R.A.; et al. Nociceptor neurons direct goblet cells via a cgrp-ramp1 axis to drive mucus production and gut barrier protection. *Cell* **2022**, *185*, 4190–4205. [CrossRef]
90. Gustafsson, J.K.; Davis, J.E.; Rappai, T.; McDonald, K.G.; Kulkarni, D.H.; Knoop, K.A.; Hogan, S.P.; Fitzpatrick, J.A.; Lencer, W.I.; Newberry, R.D. Intestinal goblet cells sample and deliver lumenal antigens by regulated endocytic uptake and transcytosis. *eLife* **2021**, *10*, 67292. [CrossRef] [PubMed]

91. Ling, Z.; Liu, X.; Cheng, Y.; Luo, Y.; Yuan, L.; Li, L.; Xiang, C. *Clostridium butyricum* combined with *Bifidobacterium infantis* probiotic mixture restores fecal microbiota and attenuates systemic inflammation in mice with antibiotic-associated diarrhea. *Biomed. Res. Int.* **2015**, *2015*, 582048. [[CrossRef](#)] [[PubMed](#)]
92. Hu, J.S.; Huang, Y.Y.; Kuang, J.H.; Yu, J.J.; Zhou, Q.Y.; Liu, D.M. *Streptococcus thermophiles* DMST-H2 promotes recovery in mice with antibiotic-associated diarrhea. *Microorganisms* **2020**, *8*, 1650. [[CrossRef](#)]
93. de Kivit, S.; Tobin, M.C.; Forsyth, C.B.; Keshavarzian, A.; Landay, A.L. Regulation of intestinal immune responses through TLR activation: Implications for pro- and prebiotics. *Front. Immunol.* **2014**, *5*, 60. [[CrossRef](#)] [[PubMed](#)]
94. Wu, Y.; He, S.; Bai, B.; Zhang, L.; Xue, L.; Lin, Z.; Yang, X.; Zhu, F.; He, P.; Tang, W.; et al. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation. *Cell. Mol. Immunol.* **2016**, *13*, 379–390. [[CrossRef](#)]
95. Teichmann, L.L.; Schenten, D.; Medzhitov, R.; Kashgarian, M.; Shlomchik, M.J. Signals via the adaptor Myd88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. *Immunity* **2013**, *38*, 528–540. [[CrossRef](#)]
96. Liao, W.; Zhang, X.; Jia, C.; Chen, W.; Cai, Y.; Zhang, H.; Wei, J.; Chen, T. *Lactobacillus rhamnosus* LC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by inhibiting the TLR9/NF- κ B signaling pathway. *Food Funct.* **2025**, *16*, 475–486. [[CrossRef](#)]
97. Zhang, Y.; Tu, S.; Ji, X.; Wu, J.; Meng, J.; Gao, J.; Shao, X.; Shi, S.; Wang, G.; Qiu, J.; et al. *Dubosiella newyorkensis* modulates immune tolerance in colitis via the L-lysine-activated AhR-IDO1-Kyn pathway. *Nat. Commun.* **2024**, *15*, 1333. [[CrossRef](#)]
98. Kordahi, M.C.; Daniel, N.; Gewirtz, A.T.; Chassaing, B. Mucus-penetrating microbiota drive chronic low-grade intestinal inflammation and metabolic dysregulation. *Gut Microbes* **2025**, *17*, 2455790. [[CrossRef](#)]
99. Zhang, J.; Zhang, D.; Xu, Y.; Zhang, J.; Liu, R.; Gao, Y.; Shi, Y.; Cai, P.; Zhong, Z.; He, B.; et al. Large-scale biosynthetic analysis of human microbiomes reveals diverse protective ribosomal peptides. *Nat. Commun.* **2025**, *16*, 3054. [[CrossRef](#)]
100. Pruss, K.M.; Chen, H.; Liu, Y.; Van Treuren, W.; Higginbottom, S.K.; Jarman, J.B.; Fischer, C.R.; Mak, J.; Wong, B.; Cowan, T.M.; et al. Host-microbe co-metabolism via MCAD generates circulating metabolites including hippuric acid. *Nat. Commun.* **2023**, *14*, 512.
101. Brial, F.; Chilloux, J.; Nielsen, T.; Vieira-Silva, S.; Falony, G.; Andrikopoulos, P.; Olanipekun, M.; Hoyle, L.; Djouadi, F.; Neves, A.L.; et al. Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health. *Gut* **2021**, *70*, 2105–2114. [[CrossRef](#)]
102. He, Y.; Zhang, X.; Zeng, X.; Huang, Y.; Wei, J.A.; Han, L.; Li, C.X.; Zhang, G.W. HuR-mediated posttranscriptional regulation of p21 is involved in the effect of glycyrrhiza uralensis licorice aqueous extract on polyamine-depleted intestinal crypt cells proliferation. *J. Nutr. Biochem.* **2012**, *23*, 1285–1293. [[CrossRef](#)] [[PubMed](#)]
103. Jeon, Y.D.; Kang, S.H.; Bang, K.S.; Chang, Y.N.; Lee, J.H.; Jin, J.S. Glycyrrhetic acid ameliorates dextran sulfate sodium-induced ulcerative colitis in vivo. *Molecules* **2016**, *21*, 523. [[CrossRef](#)] [[PubMed](#)]
104. Li, Y.; Gong, Y.; Zhang, X.; Wang, J.; Cheng, Y.; Liu, F.; Shi, X.; Xu, W.; Dong, L. Exploring the synergistic mechanism of gegen qinlian decoction on the Wnt signaling pathway using an integrated strategy of network pharmacology and RNA-seq. *J. Ethnopharmacol.* **2021**, *278*, 114283. [[CrossRef](#)] [[PubMed](#)]
105. Madsen, H.B.; Peeters, M.J.W.; Straten, P.T.; Desler, C. Nucleotide metabolism in the regulation of tumor microenvironment and immune cell function. *Curr. Opin. Biotechnol.* **2023**, *84*, 103008. [[CrossRef](#)]
106. Song, G.; Xie, Y.; Yi, L.; Cheng, W.; Jia, H.; Shi, W.; Liu, Q.; Fang, L.; Xue, S.; Liu, D.; et al. Bile acids affect intestinal barrier function through FXR and TGR5. *Front. Med.* **2025**, *12*, 1607899. [[CrossRef](#)]
107. Abdel-Khalik, J.; Crick, P.J.; Yutuc, E.; DeBarber, A.E.; Duell, P.B.; Steiner, R.D.; Laina, I.; Wang, Y.; Griffiths, W.J. Identification of 7 α ,24-dihydroxy-3-oxocholest-4-en-26-oic and 7 α ,25-dihydroxy-3-oxocholest-4-en-26-oic acids in human cerebrospinal fluid and plasma. *Biochimie* **2018**, *153*, 86–98. [[CrossRef](#)]
108. Yun, K.J.; Koh, D.J.; Kim, S.H.; Park, S.J.; Ryu, J.H.; Kim, D.G.; Lee, J.Y.; Lee, K.T. Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygenase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. *J. Agric. Food Chem.* **2008**, *56*, 10265–10272. [[CrossRef](#)]
109. Jang, S.; Kim, S.; So, B.R.; Kim, Y.; Kim, C.K.; Lee, J.J.; Jung, S.K. Sinapic acid alleviates inflammatory bowel disease (IBD) through localization of tight junction proteins by direct binding to TAK1 and improves intestinal microbiota. *Front. Pharmacol.* **2023**, *14*, 1217111. [[CrossRef](#)] [[PubMed](#)]
110. Prša, P.; Karademir, B.; Biçim, G.; Mahmoud, H.; Dahan, I.; Yalçın, A.S.; Mahajna, J.; Milisav, I. The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics. *Biochem. Pharmacol.* **2020**, *173*, 113551. [[CrossRef](#)] [[PubMed](#)]
111. Brosnan, M.E.; Brosnan, J.T. Histidine metabolism and function. *J. Nutr.* **2020**, *150*, 2570–2575. [[CrossRef](#)]
112. Niu, Y.C.; Feng, R.N.; Hou, Y.; Li, K.; Kang, Z.; Wang, J.; Sun, C.H.; Li, Y. Histidine and arginine are associated with inflammation and oxidative stress in obese women. *Br. J. Nutr.* **2012**, *108*, 57–61. [[CrossRef](#)]

113. Yoshikawa, T.; Nakamura, T.; Shibakusa, T.; Sugita, M.; Naganuma, F.; Iida, T.; Miura, Y.; Mohsen, A.; Harada, R.; Yanai, K. Insufficient intake of L-histidine reduces brain histamine and causes anxiety-like behaviors in male mice. *J. Nutr.* **2014**, *144*, 1637–1641. [[CrossRef](#)]
114. Hu, K.; Zhou, Z.; Li, H.; Xiao, J.; Shen, Y.; Ding, K.; Zhang, T.; Wang, G.; Hao, H.; Liang, Y. Regulation of histidine metabolism by *Lactobacillus Reuteri* mediates the pathogenesis and treatment of ischemic stroke. *Acta Pharm. Sin. B* **2025**, *15*, 239–255. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.